MeiraGTx Reacquires Gene Therapy Botaretigene Sparoparvovec from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment
Key Insights
MeiraGTx has entered into an asset purchase agreement with Johnson & Johnson to reacquire botaretigene sparoparvovec (bota-vec) for treating X-linked retinitis pigmentosa (search), paying $25 million upfront plus milestone payments and royalties.
The Phase 3 LUMEOS trial demonstrated statistically significant improvements across multiple vision domains, with 45% of treated patients gaining more than 10 letters in low luminance visual acuity and 40% showing improvement in two or more endpoints.
MeiraGTx plans to file for regulatory approval in the U.S., EU, and Japan immediately, targeting a potential commercial launch in 2027 for a disease affecting over 20,000 patients with no current treatment options.
MeiraGTx Holdings plc has announced the reacquisition of botaretigene sparoparvovec (bota-vec), a gene therapy for X-linked retinitis pigmentosa (search) (XLRP (search)), from Johnson & Johnson through an asset purchase agreement. The deal positions MeiraGTx to pursue immediate regulatory filings for a treatment addressing a severe unmet medical need in over 20,000 patients across the U.S. and EU who currently have no therapeutic options.
Strategic Acquisition Details
Under the asset purchase agreement, MeiraGTx will pay Johnson & Johnson $25 million upfront, plus a one-time regulatory and commercial milestone tied to U.S. approval and sales performance, along with high double-digit royalties on global net sales beginning in mid-2029. The acquisition reunites MeiraGTx with a therapy it originally helped develop through collaboration with J&J from Phase 1 onward.
"This is a unique opportunity to gain an asset at this stage in development with data supporting a meaningful benefit in patients with no alternative treatment, many of whom are waiting for this life changing therapy and hoping for expeditious approval," said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.
Phase 3 LUMEOS Trial Results
The Phase 3 LUMEOS study, a global randomized trial involving 95 patients treated bilaterally, demonstrated compelling efficacy across multiple vision domains despite missing its novel primary endpoint. While the Visual Mobility Assessment (VMA) maze test did not reach statistical significance, treated subjects were 2.4 times more likely to respond than untreated subjects, and secondary endpoints showed robust improvements.
Visual Function Improvements
The trial achieved statistically significant improvements in low luminance visual acuity (LLVA), with a p-value of 0.003. Notably, 45% of treated patients gained more than 10 letters in LLVA, while 20% achieved gains exceeding 15 letters. These improvements represent clinically meaningful changes in patients' ability to see in dim lighting conditions.
Retinal Function Enhancements
All measures of retinal sensitivity demonstrated highly significant differences between treated and untreated groups. Pointwise responders in both the central 30 degrees and full visual field showed p-values of 0.001. Mean retinal sensitivity improvements were observed in the central 10 degrees (p=0.001) and full field 90 degrees (p=0.004).
Functional Vision Benefits
Patient-reported outcomes revealed significant improvements in quality of life measures. The LLQ Extreme lighting domain score showed significant change (p=0.006), with statistically significant improvements in mobility (p=0.001), general dim lighting (p=0.007), and emotional distress (p=0.019). The IVI-A total score demonstrated significant improvement versus control at week 52 (p=0.024), with particularly strong results in emotional wellbeing questions (p=0.005).
Multi-endpoint Response Analysis
A comprehensive responder analysis revealed that 40% (22/55) of treated patients showed improvement in two or more endpoints across different vision domains, compared to 0% in the control group. This consistent pattern across various endpoints underscores the therapy's broad impact on visual function.
Clinical Significance and Expert Perspectives
Rachel Huckfeldt, M.D., Ph.D., director of Inherited Retinal Disorders Clinical Trials at Mass Eye and Ear (search) and a principal investigator in the trials, emphasized the clinical relevance of the findings. "The Phase 3 trial demonstrated meaningful improvements across multiple outcome measures with 10- and 15-letter gains in low luminance visual acuity as one example. Many participants were able to provide examples from their daily lives of the real-world impact of these gains."
Jason Menzo, CEO of Foundation Fighting Blindness, highlighted the urgent need for treatment options, stating, "The data from the LUMEOS Phase 3 study of bota-vec, reflected in both objective measures and patient-reported outcomes, point to real improvements in vision." Following the data release, the Foundation Fighting Blindness issued a public letter to J&J strongly supporting regulatory filing and approval.
Manufacturing and Regulatory Readiness
MeiraGTx's position as the commercial manufacturer of bota-vec provides significant advantages for rapid market entry. The company has successfully completed process performance qualification (PPQ) and received commercial licenses from the MHRA for its London manufacturing facility and Shannon, Ireland quality control facility. Several hundred vials of product are currently available for immediate patient treatment upon regulatory approval.
The therapy has received multiple regulatory designations supporting expedited development, including FDA Fast Track and Orphan Drug Designations, as well as EU Priority Medicines (PRIME), advanced therapy medicinal product (ATMP), and Orphan Drug Designations.
Market Opportunity and Commercial Strategy
XLRP (search) represents a concentrated market opportunity, with 40-50 centers of excellence in the EU, U.S., and Japan caring for approximately 80% of inherited retinal disease (search) patients. MeiraGTx has established relationships with key opinion leaders at most leading sites, with 32 centers participating in the Phase 3 LUMEOS study.
The company plans to file for regulatory approval in the U.S., EU, and Japan as soon as possible, targeting a potential commercial launch in 2027. This timeline aligns with expected data from MeiraGTx's AQUAx 2 pivotal study of AAV-hAQP1 for radiation-induced xerostomia (search) in the second quarter of 2027, positioning the company to become commercial-stage with two potential products addressing severe unmet needs.
Safety Profile
The Phase 3 trial confirmed bota-vec's manageable safety profile, with no new safety signals identified and an improved inflammatory profile compared to earlier Phase 1/2 studies. The safety data supports the therapy's potential for broad clinical application in the XLRP (search) patient population.
Since the LUMEOS data release, numerous investigators have reported clinically meaningful benefits in study participants, with unprecedented improvements demonstrated across all three domains of vision. This investigator enthusiasm has translated into strong support for regulatory filing to provide access to patients currently waiting for this potentially life-changing therapy.